Lake Street Initiates Coverage of AbCellera Biologics with Buy Rating
Analyst Daniel Brims at Lake Street has initiated coverage on AbCellera Biologics with a 'Buy' rating and a price target of $19.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analyst Daniel Brims at Lake Street has initiated coverage on AbCellera Biologics with a 'Buy' rating and a price target of $19.
Piper Sandler analyst Allison Bratzel maintained a bullish rating on AbCellera Biologics Inc. while increasing the price target from $12 to $20.
Multiple financial analysts have updated their ratings and price targets for AbCellera Biologics, maintaining buy recommendations with price targets ranging from $14 to $25.
Stifel has increased its price target for AbCellera Biologics Inc. from $9 to $14.
AbCellera Biologics Inc. released its financial and business results for the third quarter of 2026.
AbCellera Biologics (NASDAQ:ABCL) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga